Opzelura Ruxolitinib Cream For Vitiligo In Pakistan
Ruxolitinib 1.5%, a Janus kinase (JAK) inhibitor, is found in the prescription topical cream Opzelura, which is intended to treat nonsegmental vitiligo in adults and children 12 years of age and older. It is the first drug licensed by the FDA expressly designed to help vitiligo sufferers regain skin pigment. A prescription topical medication called Opzelura (Ruxolitinib) Cream is used to treat nonsegmental vitiligo, a kind of vitiligo in which skin patches on both sides of the body lose pigment symmetrically. It is approved for this use in a number of areas, including the U.S. FDA, for both adults and children 12 years of age and older.
How It Works
Vitiligo occurs when the immune system attacks pigment-producing cells (melanocytes). Ruxolitinib blocks JAK1 and JAK2 signaling pathways involved in this autoimmune process, helping reduce inflammation and allowing pigment cells to recover and repigment affected skin areas.
Key Features
Contains ruxolitinib 1.5% cream.
Used for nonsegmental vitiligo.
Applied twice daily to affected areas.
Can be used on up to 10% of total body surface area.
Steroid-free topical treatment.
Suitable for sensitive areas such as around the eyes and mouth (external skin only).
Benefits
Helps restore lost skin pigment (repigmentation).
May improve both facial and body vitiligo patches.
Provides a non-steroidal treatment option for long-term management.
Clinical studies showed significant repigmentation in some patients after several months of treatment.
How to Use
Apply a thin layer to affected skin twice daily.
Wash hands before and after application.
Avoid getting the cream into the eyes, mouth, or inside the nose.
Treatment often requires 24 weeks or longer before noticeable results occur.
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
1.jpg)
.jpg)
.jpg)
4.jpg)
4.jpg)
.jpg)
